exemestane Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
aromatase inhibitors 1122 107868-30-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aromasine
  • FCE 24304
  • exemestane
  • aromasin
a hormonal antineoplastic agent
  • Molecular weight: 296.41
  • Formula: C20H24O2
  • CLOGP: 3.28
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 34.14
  • ALOGS: -4.64
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.35 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 42 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Oct. 21, 1999 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 1540.03 13.28 864 40617 64062 46580519
Metastases to bone 1113.28 13.28 459 41022 17017 46627564
Breast cancer metastatic 1067.90 13.28 416 41065 13262 46631319
Metastases to liver 844.94 13.28 391 41090 19194 46625387
Neoplasm progression 707.86 13.28 383 41098 26300 46618281
Stomatitis 506.10 13.28 446 41035 67851 46576730
Osteonecrosis of jaw 496.35 13.28 334 41147 34068 46610513
Disease progression 468.98 13.28 487 40994 90813 46553768
Breast cancer 433.97 13.28 344 41137 45174 46599407
Metastases to lung 350.48 13.28 177 41304 10519 46634062
Tumour marker increased 327.57 13.28 122 41359 3419 46641162
Pneumonitis 303.87 13.28 230 41251 28190 46616391
Metastases to lymph nodes 290.75 13.28 134 41347 6497 46638084
Drug ineffective 247.65 13.28 149 41332 677689 45966892
Mucosal inflammation 207.12 13.28 212 41269 38764 46605817
Pleural effusion 206.82 13.28 308 41173 82644 46561937
Metastases to skin 182.51 13.28 62 41419 1318 46643263
Osteonecrosis 160.85 13.28 153 41328 25591 46618990
Rheumatoid arthritis 159.08 13.28 15 41466 240200 46404381
Bone pain 143.29 13.28 192 41289 46698 46597883
Lymphoedema 142.04 13.28 91 41390 8521 46636060
PIK3CA-activated mutation 141.89 13.28 42 41439 559 46644022
Breast cancer recurrent 137.75 13.28 68 41413 3843 46640738
Metastases to pleura 124.67 13.28 44 41437 1052 46643529
General physical health deterioration 123.38 13.28 299 41182 115470 46529111
Second primary malignancy 114.64 13.28 72 41409 6512 46638069
Metastases to spine 113.59 13.28 53 41428 2641 46641940
Metastases to central nervous system 111.51 13.28 87 41394 11134 46633447
Metastases to peritoneum 105.20 13.28 50 41431 2598 46641983
Palmar-plantar erythrodysaesthesia syndrome 102.76 13.28 108 41373 20343 46624238
Bone disorder 97.47 13.28 104 41377 19929 46624652
Ascites 89.86 13.28 135 41346 36449 46608132
Exposed bone in jaw 87.60 13.28 47 41434 3161 46641420
Malignant pleural effusion 84.38 13.28 42 41439 2416 46642165
Pseudocirrhosis 83.55 13.28 29 41452 659 46643922
Hot flush 82.83 13.28 143 41338 43374 46601207
Metastasis 82.30 13.28 50 41431 4262 46640319
Nail disorder 80.15 13.28 62 41419 7834 46636747
Interstitial lung disease 78.54 13.28 158 41323 53791 46590790
Off label use 77.47 13.28 137 41344 379704 46264877
Hypotension 76.51 13.28 57 41424 232532 46412049
Toxicity to various agents 72.12 13.28 50 41431 211716 46432865
Bone lesion 71.31 13.28 48 41433 4883 46639698
Hepatic lesion 68.81 13.28 43 41438 3854 46640727
Cough 68.58 13.28 393 41088 229856 46414725
Ejection fraction decreased 68.31 13.28 82 41399 17855 46626726
Bone sequestrum 67.72 13.28 32 41449 1641 46642940
Injection site pain 67.49 13.28 8 41473 107144 46537437
Lymphadenopathy mediastinal 67.42 13.28 36 41445 2398 46642183
Hormone receptor positive breast cancer 63.05 13.28 21 41460 419 46644162
Lymphangiosis carcinomatosa 62.12 13.28 27 41454 1137 46643444
Aphthous ulcer 62.01 13.28 58 41423 9490 46635091
Hyperglycaemia 59.98 13.28 110 41371 34961 46609620
Carbohydrate antigen 15-3 increased 57.84 13.28 24 41457 900 46643681
Invasive ductal breast carcinoma 57.36 13.28 46 41435 6122 46638459
Gamma-glutamyltransferase increased 56.12 13.28 101 41380 31639 46612942
Therapeutic product effect decreased 55.02 13.28 5 41476 82596 46561985
Polyneuropathy 54.09 13.28 59 41422 11585 46632996
Epistaxis 53.97 13.28 152 41329 64153 46580428
Neutropenia 52.54 13.28 259 41222 142945 46501636
Overdose 52.44 13.28 13 41468 101966 46542615
Skin toxicity 51.48 13.28 35 41446 3619 46640962
Device related thrombosis 51.30 13.28 24 41457 1203 46643378
Breast cancer female 50.27 13.28 42 41439 5921 46638660
Injection site erythema 48.26 13.28 5 41476 74422 46570159
Fall 48.11 13.28 142 41339 328955 46315626
Fatigue 46.79 13.28 779 40702 607918 46036663
Intentional overdose 45.87 13.28 3 41478 64941 46579640
Pleural neoplasm 45.09 13.28 12 41469 105 46644476
Eastern Cooperative Oncology Group performance status worsened 44.85 13.28 16 41465 395 46644186
Tooth extraction 44.50 13.28 50 41431 10143 46634438
Oral pain 42.68 13.28 78 41403 24719 46619862
Gingival swelling 42.25 13.28 32 41449 3918 46640663
Neuropathy peripheral 41.98 13.28 176 41305 90717 46553864
Drug hypersensitivity 41.87 13.28 97 41384 243728 46400853
Decreased appetite 41.75 13.28 305 41176 193531 46451050
Osteolysis 41.58 13.28 27 41454 2585 46641996
Lung infiltration 40.58 13.28 56 41425 13987 46630594
Joint swelling 40.40 13.28 53 41428 166020 46478561
Oral cavity fistula 39.36 13.28 17 41464 705 46643876
Osteitis 39.01 13.28 28 41453 3157 46641424
Treatment failure 38.87 13.28 17 41464 93070 46551511
Invasive lobular breast carcinoma 37.92 13.28 16 41465 626 46643955
Dysgeusia 37.24 13.28 99 41382 40392 46604189
Blood lactate dehydrogenase increased 37.21 13.28 66 41415 20434 46624147
Metastases to soft tissue 37.19 13.28 11 41470 146 46644435
Metastases to adrenals 36.83 13.28 16 41465 673 46643908
Product dose omission issue 36.83 13.28 58 41423 168462 46476119
Osteomyelitis 36.75 13.28 69 41412 22314 46622267
Metastases to the mediastinum 35.68 13.28 14 41467 453 46644128
Haematotoxicity 35.51 13.28 37 41444 6896 46637685
Bradycardia 34.97 13.28 8 41473 66290 46578291
Peritoneal disorder 33.81 13.28 14 41467 522 46644059
Infusion related reaction 32.97 13.28 25 41456 101183 46543398
Synovitis 32.96 13.28 7 41474 61068 46583513
Periodontitis 32.49 13.28 26 41455 3450 46641131
Somnolence 32.22 13.28 56 41425 156465 46488116
Hepatic failure 32.05 13.28 83 41398 33333 46611248
Metastases to chest wall 32.01 13.28 13 41468 461 46644120
Myocardial infarction 31.89 13.28 24 41457 97504 46547077
Therapeutic product effect incomplete 31.49 13.28 15 41466 78138 46566443
Sinusitis 30.95 13.28 42 41439 129726 46514855
Metastases to meninges 30.88 13.28 20 41461 1907 46642674
C-reactive protein increased 30.67 13.28 118 41363 58472 46586109
Arthralgia 30.25 13.28 473 41008 364130 46280451
Sequestrectomy 30.22 13.28 16 41465 1047 46643534
Seizure 30.19 13.28 39 41442 123015 46521566
Abdominal discomfort 29.40 13.28 56 41425 151109 46493472
Hospitalisation 29.06 13.28 10 41471 63375 46581206
Hallucination 28.48 13.28 5 41476 49946 46594635
Blood alkaline phosphatase increased 27.88 13.28 88 41393 39521 46605060
Weight decreased 27.81 13.28 298 41183 210551 46434030
Fibrous histiocytoma 27.59 13.28 12 41469 506 46644075
Psoriasis 27.47 13.28 18 41463 78586 46565995
Dyspnoea 27.30 13.28 624 40857 514924 46129657
Tremor 27.00 13.28 38 41443 115601 46528980
Purulent discharge 26.96 13.28 27 41454 4803 46639778
Multiple sclerosis relapse 26.87 13.28 3 41478 42122 46602459
Intentional product use issue 26.60 13.28 7 41474 52773 46591808
Trigger finger 26.47 13.28 23 41458 3419 46641162
Metastases to thorax 26.42 13.28 9 41472 193 46644388
Pain in jaw 25.87 13.28 84 41397 38288 46606293
Feeding disorder 25.56 13.28 38 41443 10156 46634425
Aspartate aminotransferase increased 25.12 13.28 137 41344 78563 46566018
Mouth ulceration 25.07 13.28 66 41415 26766 46617815
Loss of consciousness 24.84 13.28 36 41445 108202 46536379
Gingivitis 24.81 13.28 32 41449 7488 46637093
Wrong technique in product usage process 24.24 13.28 9 41472 54413 46590168
Oedema peripheral 24.05 13.28 232 41249 159474 46485107
Hepatic atrophy 23.96 13.28 9 41472 258 46644323
Tumour marker abnormal 23.91 13.28 8 41473 162 46644419
Pulmonary tumour thrombotic microangiopathy 23.85 13.28 6 41475 41 46644540
Cardio-respiratory arrest 23.35 13.28 12 41469 59857 46584724
Pancreatic neoplasm 23.30 13.28 12 41469 742 46643839
Mucosal dryness 23.28 13.28 18 41463 2272 46642309
Pulmonary mass 23.27 13.28 50 41431 17807 46626774
Lymphadenopathy 23.20 13.28 74 41407 33414 46611167
Incorrect dose administered 23.03 13.28 6 41475 45544 46599037
Suicidal ideation 22.44 13.28 11 41470 56371 46588210
Blood creatinine increased 22.40 13.28 130 41351 76273 46568308
Superinfection 22.32 13.28 16 41465 1801 46642780
Cancer pain 22.21 13.28 18 41463 2432 46642149
Psoriatic arthropathy 22.20 13.28 3 41478 36376 46608205
Neoplasm malignant 22.15 13.28 58 41423 23441 46621140
Radiation skin injury 21.85 13.28 12 41469 845 46643736
Excessive granulation tissue 21.59 13.28 12 41469 865 46643716
Suicide attempt 21.51 13.28 11 41470 55025 46589556
Confusional state 21.19 13.28 72 41409 159820 46484761
Pericardial effusion 21.04 13.28 60 41421 25483 46619098
Metastases to pelvis 20.96 13.28 8 41473 240 46644341
Drug interaction 20.91 13.28 101 41380 202993 46441588
Pathological fracture 20.46 13.28 30 41451 7920 46636661
Plasma cell myeloma 20.42 13.28 7 41474 44471 46600110
Osteopenia 20.42 13.28 46 41435 16915 46627666
Unevaluable event 19.96 13.28 8 41473 46167 46598414
Anaemia 19.73 13.28 328 41153 255451 46389130
Coma 19.53 13.28 14 41467 58335 46586246
Ocular vasculitis 19.53 13.28 5 41476 37 46644544
Actinomycosis 19.19 13.28 12 41469 1076 46643505
Radiation fibrosis 19.18 13.28 5 41476 40 46644541
Debridement 19.18 13.28 13 41468 1337 46643244
Headache 18.99 13.28 305 41176 478047 46166534
Periodontal disease 18.87 13.28 14 41467 1661 46642920
Adverse drug reaction 18.67 13.28 8 41473 44354 46600227
Bone marrow tumour cell infiltration 18.57 13.28 4 41477 12 46644569
Lung disorder 18.55 13.28 82 41399 43222 46601359
Cell marker increased 18.36 13.28 8 41473 339 46644242
Recurrent cancer 18.26 13.28 14 41467 1745 46642836
Gingival erythema 18.25 13.28 10 41471 701 46643880
Corneal epithelial microcysts 18.08 13.28 3 41478 0 46644581
Respiratory arrest 17.99 13.28 4 41477 33812 46610769
Oral disorder 17.97 13.28 28 41453 7794 46636787
Dizziness 17.84 13.28 205 41276 340209 46304372
Asthenia 17.82 13.28 381 41100 310694 46333887
Condition aggravated 17.81 13.28 136 41345 244916 46399665
Urticaria 17.81 13.28 50 41431 117842 46526739
Musculoskeletal stiffness 17.59 13.28 38 41443 97955 46546626
Bronchitis 17.49 13.28 43 41438 105936 46538645
Metastases to bone marrow 17.32 13.28 7 41474 245 46644336
Onychoclasis 17.15 13.28 22 41459 5122 46639459
Peripheral sensory neuropathy 17.11 13.28 25 41456 6578 46638003
Acute kidney injury 17.09 13.28 131 41350 235724 46408857
Blood phosphorus decreased 16.88 13.28 19 41462 3861 46640720
Concomitant disease aggravated 16.44 13.28 27 41454 7855 46636726
Heart rate decreased 16.38 13.28 4 41477 31719 46612862
Carcinoembryonic antigen increased 16.38 13.28 12 41469 1397 46643184
Loss of personal independence in daily activities 16.34 13.28 16 41465 57167 46587414
Blood pressure decreased 16.32 13.28 16 41465 57143 46587438
Lymphangitis 16.17 13.28 10 41471 880 46643701
Fluid retention 16.12 13.28 13 41468 51033 46593548
Heart rate increased 16.07 13.28 26 41455 74765 46569816
Abscess jaw 16.05 13.28 12 41469 1440 46643141
Pneumonitis chemical 16.01 13.28 6 41475 171 46644410
Pleural mass 16.00 13.28 3 41478 3 46644578
Fingerprint loss 15.82 13.28 4 41477 28 46644553
Product quality issue 15.70 13.28 6 41475 35642 46608939
Cell-mediated immune deficiency 15.69 13.28 4 41477 29 46644552
Myelosuppression 15.55 13.28 26 41455 7677 46636904
Wound treatment 15.50 13.28 6 41475 187 46644394
Cardiac arrest 15.45 13.28 36 41445 90363 46554218
Exostosis of jaw 15.45 13.28 11 41470 1225 46643356
Hepatic function abnormal 15.37 13.28 66 41415 34355 46610226
Congestive cardiomyopathy 15.34 13.28 22 41459 5691 46638890
Hypersensitivity 15.32 13.28 75 41406 150246 46494335
Radiation pneumonitis 15.28 13.28 11 41470 1246 46643335
Metastases to ovary 15.13 13.28 7 41474 342 46644239
Arthropathy 15.07 13.28 33 41448 84667 46559914
Mobility decreased 15.06 13.28 19 41462 60575 46584006
Skin lesion 14.97 13.28 55 41426 26658 46617923
Abdominal lymphadenopathy 14.85 13.28 8 41473 542 46644039
Ascariasis 14.79 13.28 3 41478 6 46644575
Acne 14.70 13.28 45 41436 19874 46624707
Fibromyalgia 14.68 13.28 7 41474 36456 46608125
Adverse event 14.65 13.28 6 41475 34178 46610403
Congenital haematological disorder 14.64 13.28 4 41477 39 46644542
Bone debridement 14.54 13.28 7 41474 374 46644207
Cardiac failure 14.51 13.28 121 41360 79827 46564754
Recall phenomenon 14.48 13.28 8 41473 570 46644011
Breast cancer stage III 14.44 13.28 11 41470 1358 46643223
Chronic obstructive pulmonary disease 14.40 13.28 18 41463 57615 46586966
Alveolar lung disease 14.39 13.28 5 41476 114 46644467
Radioisotope scan 14.29 13.28 4 41477 43 46644538
Blood glucose increased 14.16 13.28 111 41370 71902 46572679
Thrombocytopenia 14.01 13.28 173 41308 126408 46518173
Metastases to neck 13.82 13.28 4 41477 49 46644532
Computerised tomogram abnormal 13.69 13.28 13 41468 2167 46642414
Blood pressure fluctuation 13.62 13.28 5 41476 30443 46614138
Oral herpes 13.57 13.28 43 41438 19347 46625234

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC L02BG06 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Aromatase inhibitors
FDA MoA N0000175080 Aromatase Inhibitors
FDA EPC N0000175563 Aromatase Inhibitor
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:50790 aromatase inhibitors
CHEBI has role CHEBI:78298 environmental contaminants
MeSH PA D000970 Antineoplastic Agents
MeSH PA D047072 Aromatase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D004965 Estrogen Antagonists
MeSH PA D006727 Hormone Antagonists
MeSH PA D065088 Steroid Synthesis Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hormone receptor positive malignant neoplasm of breast indication 417181009
Advanced Breast Cancer Progression Post-Antiestrogen Therapy indication
Prevention of Breast Carcinoma off-label use
Pregnancy, function contraindication 289908002
Osteopenia contraindication 312894000

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Aromatase Enzyme INHIBITOR IC50 5.69 WOMBAT-PK CHEMBL
Androgen receptor Nuclear hormone receptor WOMBAT-PK

External reference:

IDSource
4021191 VUID
N0000148637 NUI
D00963 KEGG_DRUG
4021191 VANDF
C0876723 UMLSCUI
CHEBI:4953 CHEBI
EXM PDB_CHEM_ID
CHEMBL1200374 ChEMBL_ID
DB00990 DRUGBANK_ID
60198 PUBCHEM_CID
C056516 MESH_SUPPLEMENTAL_RECORD_UI
7073 IUPHAR_LIGAND_ID
6770 INN_ID
NY22HMQ4BX UNII
258494 RXNORM
180650 MMSL
31449 MMSL
8478 MMSL
d04461 MMSL
007997 NDDF
116115004 SNOMEDCT_US
387017005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Aromasin HUMAN PRESCRIPTION DRUG LABEL 1 0009-7663 TABLET 25 mg ORAL NDA 27 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 0054-0080 TABLET, FILM COATED 25 mg ORAL ANDA 27 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 0378-5001 TABLET, FILM COATED 25 mg ORAL ANDA 27 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 0832-0595 TABLET 25 mg ORAL ANDA 27 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 44278-025 TABLET 25 mg ORAL ANDA 26 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 47781-108 TABLET 25 mg ORAL ANDA 26 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 50090-5193 TABLET 25 mg ORAL ANDA 26 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 51991-005 TABLET, FILM COATED 25 mg ORAL ANDA 31 sections
Aromasin HUMAN PRESCRIPTION DRUG LABEL 1 54868-5261 TABLET 25 mg ORAL NDA 13 sections
EXEMESTANE HUMAN PRESCRIPTION DRUG LABEL 1 59762-2858 TABLET, SUGAR COATED 25 mg ORAL NDA AUTHORIZED GENERIC 28 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 63629-2056 TABLET, FILM COATED 25 mg ORAL ANDA 30 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 65162-240 TABLET, FILM COATED 25 mg ORAL ANDA 25 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 68382-383 TABLET 25 mg ORAL ANDA 25 sections
EXEMESTANE HUMAN PRESCRIPTION DRUG LABEL 1 69097-316 TABLET 25 mg ORAL ANDA 22 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 70771-1374 TABLET 25 mg ORAL ANDA 1 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 71921-190 TABLET, FILM COATED 25 mg ORAL ANDA 28 sections